Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Mark J Levis, Kathleen M. Murphy, Rosalyn Pham, Kyu Tae Kim, Adam Stine, Li Li, Ian McNiece, B Douglas Smith, Donald Small

Research output: Contribution to journalArticle

Abstract

Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute myeloid leukemia (AML) and are associated with a poor overall survival. While the normal FLT3 receptor is expressed in early hematopoietic progenitor cells, it has not been determined whether FLT3 mutations are present in the leukemic stem cells. In this study, we sorted primary AML samples into stem cell-enriched CD34+/CD38 - fractions and then analyzed the sorted and unsorted cells for the FLT3 mutant-wild-type ratio. In each case, the FLT3 mutant-wild-type ratio was not changed by selection of CD34+/CD38- cells, implying that the mutations are present in the leukemic stem cells. We used the stem cell-enriched fraction to engraft nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice and then confirmed that the FLT3/ITD mutation was present in the resultant engrafted marrow. As a final test of the importance of FLT3/ITD signaling in this engraftment model, we used a small molecule FLT3 inhibitor, CEP-701, to inhibit engraftment of FLT3/ITD stem cells. Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells.

Original languageEnglish (US)
Pages (from-to)673-680
Number of pages8
JournalBlood
Volume106
Issue number2
DOIs
StatePublished - Jul 15 2005

Fingerprint

Gene Duplication
Stem cells
Leukemia
Stem Cells
Genes
Mutation
Acute Myeloid Leukemia
SCID Mice
Hematopoietic Stem Cells
Bone Marrow
Molecules
Experiments

ASJC Scopus subject areas

  • Hematology

Cite this

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. / Levis, Mark J; Murphy, Kathleen M.; Pham, Rosalyn; Kim, Kyu Tae; Stine, Adam; Li, Li; McNiece, Ian; Smith, B Douglas; Small, Donald.

In: Blood, Vol. 106, No. 2, 15.07.2005, p. 673-680.

Research output: Contribution to journalArticle

Levis, Mark J ; Murphy, Kathleen M. ; Pham, Rosalyn ; Kim, Kyu Tae ; Stine, Adam ; Li, Li ; McNiece, Ian ; Smith, B Douglas ; Small, Donald. / Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. In: Blood. 2005 ; Vol. 106, No. 2. pp. 673-680.
@article{19e014e0d1bf48f69e6181b8dc28bb71,
title = "Internal tandem duplications of the FLT3 gene are present in leukemia stem cells",
abstract = "Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute myeloid leukemia (AML) and are associated with a poor overall survival. While the normal FLT3 receptor is expressed in early hematopoietic progenitor cells, it has not been determined whether FLT3 mutations are present in the leukemic stem cells. In this study, we sorted primary AML samples into stem cell-enriched CD34+/CD38 - fractions and then analyzed the sorted and unsorted cells for the FLT3 mutant-wild-type ratio. In each case, the FLT3 mutant-wild-type ratio was not changed by selection of CD34+/CD38- cells, implying that the mutations are present in the leukemic stem cells. We used the stem cell-enriched fraction to engraft nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice and then confirmed that the FLT3/ITD mutation was present in the resultant engrafted marrow. As a final test of the importance of FLT3/ITD signaling in this engraftment model, we used a small molecule FLT3 inhibitor, CEP-701, to inhibit engraftment of FLT3/ITD stem cells. Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells.",
author = "Levis, {Mark J} and Murphy, {Kathleen M.} and Rosalyn Pham and Kim, {Kyu Tae} and Adam Stine and Li Li and Ian McNiece and Smith, {B Douglas} and Donald Small",
year = "2005",
month = "7",
day = "15",
doi = "10.1182/blood-2004-05-1902",
language = "English (US)",
volume = "106",
pages = "673--680",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

AU - Levis, Mark J

AU - Murphy, Kathleen M.

AU - Pham, Rosalyn

AU - Kim, Kyu Tae

AU - Stine, Adam

AU - Li, Li

AU - McNiece, Ian

AU - Smith, B Douglas

AU - Small, Donald

PY - 2005/7/15

Y1 - 2005/7/15

N2 - Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute myeloid leukemia (AML) and are associated with a poor overall survival. While the normal FLT3 receptor is expressed in early hematopoietic progenitor cells, it has not been determined whether FLT3 mutations are present in the leukemic stem cells. In this study, we sorted primary AML samples into stem cell-enriched CD34+/CD38 - fractions and then analyzed the sorted and unsorted cells for the FLT3 mutant-wild-type ratio. In each case, the FLT3 mutant-wild-type ratio was not changed by selection of CD34+/CD38- cells, implying that the mutations are present in the leukemic stem cells. We used the stem cell-enriched fraction to engraft nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice and then confirmed that the FLT3/ITD mutation was present in the resultant engrafted marrow. As a final test of the importance of FLT3/ITD signaling in this engraftment model, we used a small molecule FLT3 inhibitor, CEP-701, to inhibit engraftment of FLT3/ITD stem cells. Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells.

AB - Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute myeloid leukemia (AML) and are associated with a poor overall survival. While the normal FLT3 receptor is expressed in early hematopoietic progenitor cells, it has not been determined whether FLT3 mutations are present in the leukemic stem cells. In this study, we sorted primary AML samples into stem cell-enriched CD34+/CD38 - fractions and then analyzed the sorted and unsorted cells for the FLT3 mutant-wild-type ratio. In each case, the FLT3 mutant-wild-type ratio was not changed by selection of CD34+/CD38- cells, implying that the mutations are present in the leukemic stem cells. We used the stem cell-enriched fraction to engraft nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice and then confirmed that the FLT3/ITD mutation was present in the resultant engrafted marrow. As a final test of the importance of FLT3/ITD signaling in this engraftment model, we used a small molecule FLT3 inhibitor, CEP-701, to inhibit engraftment of FLT3/ITD stem cells. Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells.

UR - http://www.scopus.com/inward/record.url?scp=22144469473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144469473&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-05-1902

DO - 10.1182/blood-2004-05-1902

M3 - Article

C2 - 15797998

AN - SCOPUS:22144469473

VL - 106

SP - 673

EP - 680

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -